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Reza Asari*, Martin Riegler and Sebastian F SchoppmannDear Editor,
With interest we read the article by Bajpai et al. [1],
entitled “ Prolonged exposure to acid and bile induces
chromosome abnormalities that precede malignant trans-
formation of benign Barrett’s epithelium”, which has
been published in the recent issue of Molecular Cytogen-
etics. Barrett’s esophagus results from gastroesophageal
reflux and harbors an increased risk for the development
of esophageal adenocarcinoma (0.5% annual cancer risk)
[2,3]. Using a fascinating in vitro approach the authors
modeled the effect of gastroesophageal reflux on immor-
talized Barrett’s esophagus cells [1]. Bajpai et al. found
that intermittent exposure of BAR-T cells to acid and
bile for 18 to 78 weeks caused a spectrum of genetic ab-
normalities typical for cancer development, including
polyploidy, loss of chromosomes and the development
of transformed clones. In addition, the genetic changes
evoked by acid and bile exposure format the target pro-
tein receptors for tumor stimulating growth factors, i.e.
epidermal growth factor (EGF), which are known to pro-
mote the growth of gastrointestinal cancers [4]. In con-
trast, unexposed cells did not exhibit these abnormalities.
Remains to be questioned, if the striking observations
made by the authors may be of clinical relevance for the
diagnosis and the therapy of Barrett’s esophagus?
Conceptually, Barrett’s esophagus results as the conse-
quence of a complex neurohumoral response of the
esophageal mucosa to gastroesophageal reflux including
acid and bile [2,3]. Thus, by theory, the removal of
Barrett’s tissue and the elimination of reflux should con-
tribute to cancer prevention. Going in line with with this
notion, recent studies found that elimination of reflux by
effective antireflux surgery contributes to increase the
yield of radiofrequency ablation to eradicate Barrett’s
esophagus, when compared to ablation and post-
ablational proton pump inhibitor (PPI) therapy, which* Correspondence: reza.asari@meduniwien.ac.at
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reproduction in any medium, provided the orsolely changes the pH of the reflux, but not the reflux
per se [3,5].
Given that the genetic abnormalities assessed by Bajpai
et al. [1] can be visualized by modern endoscopic in vivo
staining techniques, this may enable us to detect tissue
at risk for cancer development [4,6,7] and specifically
target our therapies (i.e. ablation, endoscopic resection)
towards these areas [3]. Therefore a risk profile- (anam-
nestic, demographic & endoscopic, esophageal function
tests characteristics) [3] and endoscopically visualized
genetic profile- based tailored management of Barrett’s
esophagus for cancer prevention may be realistic in the
future [1,4,6,7]. Thus, Barrett’s positive individuals with
increased reflux due to severely impaired function of the
esophagus may be offered elimination of acid and bile
reflux by an effective anti reflux surgery prior to ablation
[3,5]. In contrast, ablation and subsequent PPI therapy
seems reasonable for those with Barrett’s esophagus and
normal esophageal function and reflux monitoring [3].
Endoscopic radiofrequency ablation would then be
targeted to in vivo staining positive genetic abnormal
areas [1,6,7]. Taken together, time seems ready to design
prospective clinical trials to assess the impact of the
above mentioned biological markers for cancer preven-
tion. The authors are kindly asked to comment on the
above considerations.
Sincerely,
Reza Asari, Martin Riegler, Sebastian F. Schoppmann.
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